Saturday, October 3, 2026

EUR/JPY Is 3% Down In The Last 21 Sessions

ViaNews Editorial Team

January 2, 2024

EUR/JPY Is 3% Down In The Last 21 Sessions

(VIANEWS) - EUR/JPY (EURJPY) has been up by 3.24% for the last 21 sessions. At 03:08 EST on Tuesday, 2 January, EUR/JPY (EURJPY) is $155.97.

EUR/JPY's yearly highs and lows, it's 13.514% up from its 52-week low and 5.056% down from its 52-week high.

Volatility

EUR/JPY's last week, last month's, and last quarter's current intraday variation average was a negative 0.17%, a negative 0.17%, and a positive 0.44%, respectively.

EUR/JPY's highest amplitude of average volatility was 0.42% (last week), 0.61% (last month), and 0.44% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/JPY's Forex is considered to be overbought (>=80).

News about

  • According to FXStreet on Tuesday, 2 January, "The Japanese Yen (JPY) ticks lower against its American counterpart and lifts the USD/JPY pair beyond mid-142.00s amid lighter trading volumes during the Asian session on Monday. ", "The latter should act as a key pivotal point, which if broken decisively could make the USD/JPY pair vulnerable to accelerate the fall towards the 139.35 region en route to the 139.00 mark, the 138.75 area and the 138.00 mark (July 28 low)."

More news about EUR/JPY (EURJPY).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com